Professor of Practice lecture: Timo Lappalainen


11 tammikuun, 2024    
12:00 pm - 1:00 pm
Professor of Practice lecture: Timo Lappalainen

January 11th at 12:00
On-site event
Lauren 2 auditorium, Medisiina D

DI Timo Lappalainen, who has been the CEO of Orion Corporation for 15 years, has started as an InFLAMES Professor of Practice at the Faculty of Medicine from the beginning of this year. He will give his Professor of Practice seminar Leading a Pharma Company on January 11th from 12:00–13:00. Welcome to the seminar and get to know his remarkable career and expertise.

Coffee, tea and sandwiches will be served before the seminar starting at 11:30. For catering purposes, please register for the seminar before 9.1.2024 via the following link:

The seminar is open for all!


Professor of Practice Timo Lappalainen’s journey in the pharmaceutical industry spans nearly three decades, encompassing roles in international marketing, business development, finance, and, for the last 15 years, as the CEO of Orion Corporation. Orion approaches the pharma market with both generic products for a broad array of therapies and innovative products focused on certain oncology and neurology-related diseases. During his tenure at Orion, Timo and his team were involved in corporate development actions, focused on R&D and production assets, and invested substantial capital in both immaterial and material assets. They were also fortunate to hire and retain exceptionally qualified professionals who researched, developed, manufactured, and commercialized the innovations of the company.

Beyond Orion, Timo extends his contributions as a board member, chair of audit committee, member of the personnel and renumeration committee of Kemira Corporation. Kemira, listed on the main board of Helsinki Nasdaq, specializes in safe, sustainable chemistries. Additionally, he serves as the Chairman of the Board and chairs the Human Resources Committee at the Finnish Fair Corporation, responsible for managing the Helsinki Convention Center. His involvement extends further as a board member of the Finnish Foundation for Cardiovascular Research.